loader
report-image

Pulmonary Arterial Hypertension Market Size - By Drug Type(Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators), by Route of Administration(Oral, Intravenous/ subcutaneous, Inhalational), by Distribution Channel(Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) & Region - Forecasts 2023 - 2033

  • PUBLISHED ON
  • 2022-09-05
  • NO OF PAGES
  • 276
  • CATEGORY
  • Healthcare & Life Sciences

 

Global Pulmonary Arterial Hypertension Market Analysis by Drug Type, Route Of Administration, Distributional Channel, Region and segments forecast till 2033

 

Market Overview

The global pulmonary arterial hypertension market was worth USD 7,000 million in 2022 and is poised to expand at a CAGR of 5.2% over the forecast period of 2023-2033, thereby amassing USD 11,000 million by end of the assessment period.

 

Report Scope

Report Attributes

Description

Market Forecast in 2022

USD 7,000 Million

Market Forecast in 2033

USD 11,000 Million

CAGR % 2023-2033

5.2%

Base Year

2022

Historic Data

2020-2021

Forecast Period

2023-2033

Report USP

Product Product, end-user industry, company share, company heatmap, company Capacity Technology Product capacity, growth factors and more

Segments Covered

drug type, route of administration, distributional channel

Regional Scope

North America, Europe, APAC, South America and Middle East and Africa

Country Scope

U.S.; Canada; U.K.; Germany; France; Italy; Spain; Benelux; Nordic Countries; Russia; China; India; Japan; South Korea; Australia; Indonesia; Thailand; Mexico; Brazil; Argentina; Saudi Arabia; UAE; Egypt; South Africa; Nigeria

Key Companies

Arena Pharmaceuticals (Pfizer Inc.), Bayer AG, GlaxoSmithKline plc, Johnson & Johnson (Actelion Pharmaceuticals, Ltd.), Merck & Co., Inc., United Therapeutics Corporation, Gilead Sciences, Inc., Sandoz AG (Novartis), Lupin, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, DAIICHI SANKYO COMPANY, LIMITED, Dr. Reddy’s Laboratories Ltd., Par Pharmaceutical, Zydus Pharmaceuticals, Inc., Hikma Pharmaceuticals PLC, Mylan N.V., Sigmapharm Laboratories, LLC., and Others. 

 

Global Pulmonary Arterial Hypertension Market: Description

Pulmonary arterial hypertension (PAH) refers to a progressive medical disorder characterized by abnormally high blood pressure in the pulmonary artery. It predominantly occurs when the small arteries present across the lungs narrow down, thereby increasing resistance to blood flow through the lungs. Hence, to overcome this resistance, blood pressure increases in the right ventricle of the heart along with the pulmonary artery. The major symptoms associated with PAH are dyspnea, dizziness, irregular heartbeats, swelling in legs, and chest pain.

The primary factors aiding the industry growth are surging prevalence of PAH worldwide, rise in geriatric population, drug developments along with technological advancements in the field. Moreover, unhealthy lifestyle habits of the masses, rising rate of product approvals by regulatory bodies, and increase in research & development investments in the healthcare sector are positively swaying the market dynamics. On the contrary, side effects pertaining to PAH drugs and patent expiration of drug molecule are likely to hinder the industry progression in the forthcoming years.

With rapid urbanization, there has been a drastic change in the lifestyle habits of the masses. Increasing consumption of ready to eat food and hectic work schedule is severely impacting the health of individuals across the globe. Moreover, excessive smoking and alcohol consumption along with unhealthy diet are the major catalysts aiding the overall market expansion.

Prominent players and medical research entities are increasing their focus towards the development of efficient drugs to treat PAH. They are steadily emphasizing upon the identification of new molecular pathways to develop better treatment options. These factors in turn are accelerating the progression of pulmonary arterial hypertension industry.

 

Global Pulmonary Arterial Hypertension Market- Segmental Analysis:

Drug Type Insights

The prostacyclin and prostacyclin analogs segment is anticipated to garner significant returns over the forecast duration. This is credited to the escalating demand of this drugs due to their efficacy and easy approval process.

 

Route of Administration Insights

The oral segment is presently dominating the market in terms of revenue share ascribing to the rising availability of oral formulations and surging patient preference for oral medicines.

 

Distributional Channel Insights

The online pharmacies segment is slated to register notable gains over 2023-2033 due to increase in internet penetration and widespread adoption of smart devices.

 

Regional Insights

Considering the geographical frame of reference, the business sphere is divided into North America, Middle East & Africa, Latin America, Europe, and Asia Pacific. Among these, North America is projected to showcase lucrative expansion trends attributing to growing cognizance of PAH, favorable medical reimbursement policies, and surging prevalence of infectious and chronic diseases.

Also, Asia Pacific is anticipated to amplify with a significant CAGR owing to the presence of prominent pharmaceutical companies, surging consumption of generics, and rapidly evolving healthcare infrastructure in nations such as China, India, and Japan.

 

Competitive Analysis

The noteworthy players influencing the trends of this market sphere are Arena Pharmaceuticals (Pfizer Inc.), Bayer AG, GlaxoSmithKline plc, Johnson & Johnson (Actelion Pharmaceuticals, Ltd.), Merck & Co., Inc., United Therapeutics Corporation, Gilead Sciences, Inc., Sandoz AG (Novartis), Lupin, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, DAIICHI SANKYO COMPANY, LIMITED, Dr. Reddy’s Laboratories Ltd., Par Pharmaceutical, Zydus Pharmaceuticals, Inc., Hikma Pharmaceuticals PLC, Mylan N.V., Sigmapharm Laboratories, LLC., and Others. 

 

Global Pulmonary Arterial Hypertension Market- Segmental Analysis

By drug type

Endothelin Receptor Antagonists (ERAs)

• PDE-5 Inhibitors

• Prostacyclin and Prostacyclin Analogs

• SGC Stimulators

• Others

 

By route of administration

• Oral

• Intravenous/subcutaneous

• Inhalational

 

By distributional channel

Hospital Pharmacies

• Retail Pharmacies

• Online Pharmacies

 

Why to buy this Report?

Market research: The report provides valuable insights into market trends, growth opportunities, and competitive landscapes. By reading a technology report, businesses and investors can gain a better understanding of the market they are operating in or considering entering, and make more informed decisions based on data and analysis.

Competitive analysis: The report reports provide detailed information on competitors' strengths, weaknesses, and strategies, which can help businesses identify potential threats and opportunities in the market.

Innovation: The report provides insights into emerging technologies and trends, which can help businesses stay up-to-date with the latest developments and make informed decisions about where to invest their resources.

Due diligence: The report can be used by investors and acquirers as part of their due diligence process when considering investing in or acquiring a technology company. These reports can provide valuable information on the company's financials, technology, market position, and other key factors.

1. Global Pulmonary Arterial Hypertension Market Introduction and Market Overview

1.1. Objective of the Market Research Study

1.2. Pulmonary Arterial Hypertension Market Definition & Description

1.3. Research Data Parameters & Reporting Timelines

1.3.1. Historical Data Reporting Years – 2020 to 2021

1.3.2. Projected Data Reporting Years – 2022 to 2033

1.3.3. Reporting Data Parameters – Value (US$ Million)

1.4. Global Pulmonary Arterial Hypertension Market Scope and Market Estimation

1.4.1. Global Pulmonary Arterial Hypertension Overall Market Size (US$ Million), Market CAGR (%), Market Estimates & Forecast (2020 to 2033)

1.4.2. Global Pulmonary Arterial Hypertension Market Revenue Share (%) and Growth Rate (Y-o-Y) from 2020 to 2033

1.5. Pulmonary Arterial Hypertension Market Segmentation

1.5.1. Drug Type of Global Pulmonary Arterial Hypertension Market

1.5.2. Route of Administration of Global Pulmonary Arterial Hypertension Market

1.5.3. Distribution Channel of Global Pulmonary Arterial Hypertension Market

1.5.4. Key Regions of Global Pulmonary Arterial Hypertension Market

 

2. Global Pulmonary Arterial Hypertension Market - Executive Summary

2.1. Global Pulmonary Arterial Hypertension Market – Summary & Snapshot

2.2. Global Pulmonary Arterial Hypertension Market, By Drug Type (US$ Million)

2.3. Global Pulmonary Arterial Hypertension Market, By Route of Administration (US$ Million)

2.4. Global Pulmonary Arterial Hypertension Market, By Distribution Channel (US$ Million)

2.5. Global Pulmonary Arterial Hypertension Market, By Geography (US$ Million)

2.6. Global Pulmonary Arterial Hypertension Market Outlook & Future Opportunities

 

3. Pulmonary Arterial Hypertension Market Trends, Outlook, and Factors Analysis

3.1. Global Pulmonary Arterial Hypertension Market Industry Development Trends under COVID-19 Outbreak

3.1.1. Global COVID-19 Status Overview

3.1.2. Influence of COVID-19 Outbreak on Global Pulmonary Arterial Hypertension Market Industry Development

3.1.3. Pre & Post COVID-19 Trends and Scenarios

3.2. Pulmonary Arterial Hypertension Market Dynamics (Growth Impacting Factors & Rationales)

3.2.1. Drivers

3.2.1.1. Rising cases of heart problems leading to pulmonary arterial hypertension (PHA) is expected to drive the market growth

3.2.1.2. Growing government initiatives are anticipated to trigger the market growth

3.2.2. Restraints

3.2.2.1. Patent expiration of drug molecule and side effects associated with the drugs is anticipated to hamper the market growth

3.2.3. Opportunities

3.2.3.1. High proportion of children suffering from untreated PAH offers immense market expansion opportunities

3.2.4. Impact Analysis of Drivers and Restraints

3.3. Ecosystem/ Value Chain Analysis

3.4. Porter’s Five Forces Analysis

3.5. SWOT Analysis

3.6. PEST Analysis

3.7. Average Selling Prices and Pricing Trends Analysis of Pulmonary Arterial Hypertension Market

3.8. Technological Roadmap

3.9. Key Investment Pockets of Pulmonary Arterial Hypertension Market

3.9.1. By Drug Type

3.9.2. By Route of Administration

3.9.3. By Distribution Channel

3.9.4. By Regions

 

4. Global Pulmonary Arterial Hypertension Market: Estimates & Historic Trend Analysis (2020 to 2021)

4.1. Global Pulmonary Arterial Hypertension Market, 2020 – 2021 (US$ Million)

4.2. Global Pulmonary Arterial Hypertension Market, By Drug Type, 2020 to 2021 (US$ Million)

4.3. Global Pulmonary Arterial Hypertension Market, By Route of Administration, 2020 to 2021 (US$ Million)

4.4. Global Pulmonary Arterial Hypertension Market, By Distribution Channel, 2020 to 2021 (US$ Million)

4.5. Global Pulmonary Arterial Hypertension Market, By Region, 2020 to 2021 (US$ Million)

 

5. Global Pulmonary Arterial Hypertension Market Estimates & Forecast Trend Analysis, by Drug Type

5.1. Global Pulmonary Arterial Hypertension Market Share (%) Estimates and Forecasts, by Drug Type, 2022 & 2033

5.2. Global Pulmonary Arterial Hypertension Market Revenue (US$ Million) Estimates and Forecasts, by Drug Type, 2022 to 2033

5.2.1. Endothelin Receptor Antagonists (ERAs)

5.2.2. PDE-5 Inhibitors

5.2.3. Prostacyclin and Prostacyclin Analogs

5.2.4. SGC Stimulators

5.2.5. Others

 

6. Global Pulmonary Arterial Hypertension Market Estimates & Forecast Trend Analysis, by Route of Administration

6.1. Global Pulmonary Arterial Hypertension Market Share (%) Estimates and Forecasts, by Route of Administration, 2022 & 2033

6.2. Global Pulmonary Arterial Hypertension Market Revenue (US$ Million) Estimates and Forecasts, by Route of Administration, 2022 to 2033

6.2.1. Oral

6.2.2. Intravenous/ subcutaneous

6.2.3. Inhalational

 

7. Global Pulmonary Arterial Hypertension Market Estimates & Forecast Trend Analysis, by Distribution Channel

7.1. Global Pulmonary Arterial Hypertension Market Share (%) Estimates and Forecasts, by Distribution Channel, 2022 & 2033

7.2. Global Pulmonary Arterial Hypertension Market Revenue (US$ Million) Estimates and Forecasts, by Distribution Channel, 2022 to 2033

7.2.1. Hospital Pharmacies

7.2.2. Retail Pharmacies

7.2.3. Online Pharmacies

 

8. Global Pulmonary Arterial Hypertension Market Analysis and Forecast, by Region

8.1. Global Pulmonary Arterial Hypertension Market Share (%) Estimates and Forecasts, by Region, 2022 & 2033

8.2. Global Pulmonary Arterial Hypertension Market Revenue (US$ Million) Estimates and Forecasts, by Region, 2022 to 2033

8.2.1. North America

8.2.2. Europe

8.2.3. Asia Pacific

8.2.4. Middle East and Africa

8.2.5. Latin America

 

9. North America Pulmonary Arterial Hypertension Market: Estimates & Forecast Trend Analysis

9.1. North America Pulmonary Arterial Hypertension Market Assessments & Key Findings

9.2. North America Pulmonary Arterial Hypertension Market Share (%) Estimates and Forecasts, 2022 & 2033

9.3. North America Pulmonary Arterial Hypertension Market Size Estimates and Forecast (US$ Million) (2022 to 2033)

9.3.1. By Drug Type

9.3.2. By Route of Administration

9.3.3. By Distribution Channel

9.3.4. By Major Country

9.3.4.1. The U.S.

9.3.4.2. Canada

 

10. Europe Pulmonary Arterial Hypertension Market: Estimates & Forecast Trend Analysis

10.1. Europe Pulmonary Arterial Hypertension Market Assessments & Key Findings

10.2. Europe Pulmonary Arterial Hypertension Market Share (%) Estimates and Forecasts, 2022 & 2033

10.3. Europe Pulmonary Arterial Hypertension Market Size Estimates and Forecast (US$ Million) (2022 to 2033)

10.3.1. By Drug Type

10.3.2. By Route of Administration

10.3.3. By Distribution Channel

10.3.4. By Major Country

10.3.4.1. Germany

10.3.4.2. The U.K.

10.3.4.3. France

10.3.4.4. Italy

10.3.4.5. Spain

10.3.4.6. Rest of Europe (includes all other European countries)

 

11. Asia Pacific Pulmonary Arterial Hypertension Market: Estimates & Forecast Trend Analysis

11.1. Asia Pacific Pulmonary Arterial Hypertension Market Assessments & Key Findings

11.2. Asia Pacific Pulmonary Arterial Hypertension Market Share (%) Estimates and Forecasts, 2022 & 2033

11.3. Asia Pacific Pulmonary Arterial Hypertension Market Size Estimates and Forecast (US$ Million) (2022 to 2033)

11.3.1. By Drug Type

11.3.2. By Route of Administration

11.3.3. By Distribution Channel

11.3.4. By Major Country

11.3.4.1. China

11.3.4.2. Japan

11.3.4.3. India

11.3.4.4. ASEAN

11.3.4.5. South Korea

11.3.4.6. Rest of Asia Pacific (includes all other Asia Pacific countries)

 

12. Middle East & Africa Pulmonary Arterial Hypertension Market: Estimates & Forecast Trend Analysis

12.1. Middle East & Africa Pulmonary Arterial Hypertension Market Assessments & Key Findings

12.2. Middle East & Africa Pulmonary Arterial Hypertension Market Share (%) Estimates and Forecasts, 2022 & 2033

12.3. Middle East & Africa Pulmonary Arterial Hypertension Market Size Estimates and Forecast (US$ Million) (2022 to 2033)

12.3.1. By Drug Type

12.3.2. By Route of Administration

12.3.3. By Distribution Channel

12.3.4. By Major Country

12.3.4.1. GCC

12.3.4.2. South Africa

12.3.4.3. Egypt

12.3.4.4. Rest of Middle East & Africa (includes all other Middle East & Africa countries)

 

13. Latin America Pulmonary Arterial Hypertension Market: Estimates & Forecast Trend Analysis

13.1. Latin America Market Assessments & Key Findings

13.2. Latin America Pulmonary Arterial Hypertension Market Share (%) Estimates and Forecasts, 2022 & 2033

13.3. Latin America Pulmonary Arterial Hypertension Market Size Estimates and Forecast (US$ Million) (2022 to 2033)

13.3.1. By Drug Type

13.3.2. By Route of Administration

13.3.3. By Distribution Channel

13.3.4. By Major Country

13.3.4.1. Brazil

13.3.4.2. Mexico

13.3.4.3. Rest of Latin America (includes all other Latin America countries)

 

14. Competitive Landscape

14.1. Pulmonary Arterial Hypertension Market Revenue Share Analysis (%), by Major Players (2021)

14.2. Pulmonary Arterial Hypertension Market Competition Matrix, by Leading Players

14.3. Pulmonary Arterial Hypertension List of Emerging, Prominent and Leading Players

14.4. Major Mergers & Acquisitions, Partnership, Joint Venture, Expansions, Deals, Recent Developments, etc.

 

15. Company Profiles

15.1. Arena Pharmaceuticals (Pfizer Inc)

15.1.1. Company Overview & Insights

15.1.2. Financial Performance

15.1.3. Product / Service Portfolio

15.1.4. Geographical Footprint & Share

15.1.5. Strategic Initiatives & Key Developments

*Similar details would be provided for all the players mentioned below

15.2. Bayer AG

15.3. GlaxoSmithKline plc

15.4. Johnson & Johnson (Actelion Pharmaceuticals, Ltd.)

15.5. Merck & Co., Inc

15.6. United Therapeutics Corporation

15.7. Gilead Sciences, Inc.

15.8. Sandoz AG (Novartis)

15.9. Lupin

15.10. Teva Pharmaceutical Industries Ltd.

15.11. Eli Lilly and Company

15.12. DAIICHI SANKYO COMPANY, LIMITED

15.13. Dr. Reddy’s Laboratories Ltd.

15.14. Par Pharmaceutical

15.15. Zydus Pharmaceuticals, Inc.

15.16. Hikma Pharmaceuticals PLC

15.17. Mylan N.V.

15.18. Sigmapharm Laboratories, LLC.

15.19. Others

 

16. Assumptions and Research Methodology

16.1. Data Mining

16.2. Secondary Research

16.3. Primary Research

16.4. Subject Matter Expert Advice

16.5. Quality Check

16.6. Final Review

16.7. Data Triangulation

16.8. Bottom-Up Approach

16.9. Top Down Approach

16.10. Research Flow

16.11. Key Insights from Industry Experts

16.12. Data Sources

16.13. Assumptions

16.14. Limitations

 

17. Conclusions and Recommendations

17.1. Key Research Findings and Conclusion

17.2. Key Insights & Recommendations from Analysts

Quality Assurance Process

  1. We Market Research’s Quality Assurance program strives to deliver superior value to our clients.

We Market Research senior executive is assigned to each consulting engagement and works closely with the project team to deliver as per the clients expectations.

Market Research Process




We Market Research monitors 3 important attributes during the QA process- Cost, Schedule & Quality. We believe them as a critical benchmark in achieving a project’s success.

To mitigate risks that can impact project success, we deploy the follow project delivery best practices:
  • Project kickoff meeting with client
  • Conduct frequent client communications
  • Form project steering committee
  • Assign a senior SR executive as QA Executive
  • Conduct internal editorial & quality reviews of project deliverables
  • Certify project staff in SR methodologies & standards
  • Monitor client satisfaction
  • Monitor realized value post-project

Case Study- Automotive Sector

One of the key manufacturers of automotive had plans to invest in electric utility vehicles. The electric cars and associated markets being a of evolving nature, the automotive client approached We Market Research for a detailed insight on the market forecasts. The client specifically asked for competitive analysis, regulatory framework, regional prospects studied under the influence of drivers, challenges, opportunities, and pricing in terms of revenue and sales (million units).

Solution

The overall study was executed in three stages, intending to help the client meet its objective of precisely understanding the entire market before deciding on an investment. At first, secondary research was conducted considering political, economic, social, and technological parameters to get a gist of the various aspects of the market. This stage of the study concluded with the derivation of drivers, opportunities, and challenges. It also laid substantial emphasis on understanding and collecting data not only on a global scale but also on the regional and country levels. Data Extraction through Primary Research

The second stage involved primary research in which several market players and automotive parts suppliers were contacted to study their viewpoint concerning the development of their market and production capacity, clientele, and product line. This stage concluded in a brief understanding of the competitive ecosystem and also glanced through the strategies and pricing of the companies profiled.

Market Estimates and Forecast

In the final stage of the study, market forecasts for the electric utility were derived using multiple market engineering approaches. This data helped the client to get an overview of the market and accelerate the process of investment.

Case Study- ICT Sector

Business process outsourcing, being one of the lucrative markets from both supply- and demand- side, has appealed to various companies. One of the prominent corporations based out of Japan approached us with their requirements regarding the scope of the procurement outsourcing market for around 50 countries. Additionally, the client also sought key players operating in the market and their revenue breakdown in terms of region and application.


Business Solution

An exhaustive market study was conducted based on primary and secondary research that involved factors such as labor costs in various countries, skilled and technical labors, manufacturing scenario, and their respective contributions in the global GDP. A comparative study of the market was conducted from both supply- and demand side, with the supply-side comprising of notable companies, such as GEP, Accenture, and others, that provide these services. On the other hand, large manufacturing companies from them demand-side were considered that opt for these services.


Conclusion

The report aided the client in understanding the market trends, including country-level business scenarios, consumer behavior, and trends in 50 countries. The report also provided financial insights of crucial players and detailed market estimations and forecasts till 2033.


CHOOSE LICENSE TYPE
QLOUD
Pricing

Select a license type that suits your business needs

Single User Access

US $4750

Only Four Thousand Seven Hundred Fifty US dollar

  • 1 User access
  • 15% Additional Free Customization
  • Free Unlimited post-sale support
  • 100% Service Guarantee until achievement of ROI
Multi User Cost

US $5750

Only Five Thousand Seven Hundred Fifty US dollar

  • 5 Users access
  • 25% Additional Free Customization
  • Access Report summaries for Free
  • Guaranteed service
  • Dedicated Account Manager
  • Discount of 20% on next purchase
  • Get personalized market brief from Lead Author
  • Printing of Report permitted
  • Discount of 20% on next purchase
  • 100% Service Guarantee until achievement of ROI
Enterprise User Cost

US $7750

Only Seven Thousand Seven Hundred Fifty US dollar

  • Unlimited User Access
  • 30% Additional Free Customization
  • Exclusive Previews to latest or upcoming reports
  • Discount of 30% on next purchase
  • 100% Service Guarantee until achievement of ROI